Scarica l'app Stockscreener
25.45
2.54%
0.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$24.82
Aprire:
$24.7
Volume 24 ore:
2.80M
Relative Volume:
1.31
Capitalizzazione di mercato:
$4.29B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
141.39
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
+7.66%
1M Prestazione:
+21.31%
6M Prestazione:
+33.25%
1 anno Prestazione:
+66.45%
Intervallo 1D:
$24.62
$25.88
Intervallo di 1 settimana:
$23.28
$25.88
Portata 52W:
$13.40
$25.88
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
25.45 | 4.19B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD By Investing.com - Investing.com Australia
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD - Investing.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2025 - BioSpace
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
JMP Securities Boosts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $38.00 - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $17.00 at The Goldman Sachs Group - MarketBeat
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
UBS Raises Price Target for ACADIA Pharmaceuticals to $36 - AInvest
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
Acadia Pharmaceuticals shares rise 1.05% intraday after UBS raised price target to $36. - AInvest
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript - Insider Monkey
Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
ACADIA Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Shares Surge 3.07% to New Peak on Q2 Earnings, Patent Wins - AInvest
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - MSN
Acadia Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates - MSN
Acadia Pharmaceuticals stock price target raised to $24 from $18 at Stifel - Investing.com Canada
Mizuho Maintains Neutral Rating, Raises Price Target for ACADIA Pharmaceuticals to $24 - AInvest
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $38 - 富途牛牛
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings By Investing.com - Investing.com Canada
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings - Investing.com
Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP - TipRanks
Acadia Pharmaceuticals price target raised to $27 from $23 at BofA - TipRanks
Acadia Pharmaceuticals Beats Q2 Earnings ForecastsNews and Statistics - IndexBox
Acadia Pharmaceuticals stock price target raised to $38 from $37 at Citizens JMP - Investing.com Australia
Acadia Pharmaceuticals shares rise 2.10% premarket after FDA approves expanded indication for AJOVY. - AInvest
Acadia Pharmaceuticals Raises Guidance As Sales Climb In Q2 - Finimize
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts By Investing.com - Investing.com Canada
Instagram Rolls Out New Features for Personalized Content Discovery and Sharing - AInvest
ACADIA Pharmaceuticals Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ACAD) - Seeking Alpha
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts - Investing.com
Transcript : ACADIA Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Acadia Pharmaceuticals Q2 Earnings Fall, Revenue Rises - MarketScreener
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - BioSpace
ACADIA Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Neuren Pharma shares soar on Q2 royalties growth - Capital Brief
Revamping Acadia - BioCentury
Acadia Pharmaceuticals Q2 2025 slides: revenue up 9%, raises full-year guidance - Investing.com Australia
Acadia: Q2 Earnings Snapshot - The Washington Post
Acadia Pharmaceuticals to Present at Canaccord Genuity 45th Annual Growth Conference - AInvest
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Lelezard
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer - Business Wire
ACADIA Pharmaceuticals Inc. At Decision Level — Rebound or ResistanceReal Profit Trade Plan Suggestions Shared Widely - metal.it
Does ACADIA Pharmaceuticals Inc. stock perform well during market downturnsDiscover high-growth stocks for your portfolio - Jammu Links News
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):